Avid Bioservices Inc Stock
€6.55
Your prediction
Avid Bioservices Inc Stock
Pros and Cons of Avid Bioservices Inc in the next few years
Pros
Cons
Performance of Avid Bioservices Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Avid Bioservices Inc | 3.850% | - | - | - | - | - | - |
Gritstone Oncology Inc | -6.610% | -4.678% | -6.857% | 6.722% | 31.593% | -73.850% | - |
Rockwell Medical Inc. | 1.330% | 9.901% | 25.121% | -6.386% | -12.795% | -85.658% | -97.163% |
Innoviva Inc. | 0.700% | 2.899% | -0.699% | 36.538% | -2.740% | 42.000% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.A general assessment of Avid Bio’s (US symbol: PPHMD) financial metrics reveals a fairly stable pharmaceutical company. The metrics indicate a company with a consistent financial track record, although there are areas of concern. For instance, a PERatio of 31.9728 is on the high side, which flags a need for caution as higher PE ratios generally signal overpriced stocks. Nevertheless, before rushing to conclusions, a detailed probing into the pros and cons of Avid Bio’s financial statements is necessary.
Several indicators reflect positively on Avid Bio’s fiscal health. A notable highlight is the firm's Market Capitalization, standing at a sizeable 219.3842 million. This points to the market’s optimistic perception of Avid Bio, supporting the company’s overall growth potential and future economic prospects.
The Revenue per share TTM (Trailing Twelve Months) at 2.405 further strengthens Avid Bio’s position. This indicator, along with Quarterly Revenue Growth YOY (Year on Year) at 0.028, affirms the company's reliable revenue generation capacity. Correspondingly, a Gross Profit TTM of 31,480,000 showcases the operational success in terms of revenue realization after accounting for direct costs.